KALV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.14 USD with a low forecast of 27.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 16.900

Low

27.00

Averages

31.14

High

39.00

Current: 16.900

Low

27.00

Averages

31.14

High

39.00

Oppenheimer

Outperform

maintain

$44 -> $50

2025-12-04

Reason

Oppenheimer

Price Target

$44 -> $50

2025-12-04

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pharvaris (PHVS) to $50 from $44 and keeps an Outperform rating on the shares. The firm notes the company reported positive top-line results for the pivotal RAPIDe-3, study of deucrictibant in the on-demand setting, hitting statistical significance across all primary and secondary endpoints. This result is a clear win for Pharvaris in the on-demand setting where it will compete with Kalvista's (KALV) recently launched Ekterly, with positive read-across to deucrictibant in the larger prophylactic setting, with those pivotal results anticipated in the second half of 2026.

Citizens JMP

Outperform

maintain

$29 -> $28

2025-11-11

Reason

Citizens JMP

Price Target

$29 -> $28

2025-11-11

maintain

Outperform

Reason

Citizens JMP lowered the firm's price target on KalVista to $28 from $29 and keeps an Outperform rating on the shares. Early demand for Ekterly looks strong, with 937 start forms as of the end of October, covering roughly 8% of the diagnosed U.S. hereditary angioedema population, the analyst tells investors in a research note. The 937 start forms represent about $31M in potential revenue, the firm notes, adding that the early demand is "promising."

BofA

Buy

downgrade

$36 -> $29

2025-10-22

Reason

BofA

Price Target

$36 -> $29

2025-10-22

downgrade

Buy

Reason

BofA lowered the firm's price target on KalVista to $29 from $36 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.

Citizens JMP

Jonathan Wolleben

Outperform

maintain

$27 -> $28

2025-09-12

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$27 -> $28

2025-09-12

maintain

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben raised the firm's price target on KalVista to $28 from $27 and keeps an Outperform rating on the shares. Ekterly has seen robust early demand with 460 patient start forms which represents about $31M in potential revenue, but all patients get 4 doses of free drug and realization of that revenue depends on having and treating attacks and payer access, the analyst tells investors in a research note. The firm adds that consensus estimates near-term will be "unreliable" as KalVista is changing its fiscal year reporting.

Citizens JMP

Jonathan Wolleben

Outperform

maintain

$19 -> $27

2025-07-08

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$19 -> $27

2025-07-08

maintain

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben raised the firm's price target on KalVista to $27 from $19 and keeps an Outperform rating on the shares. Ekterly is poised for a strong launch given the unmet need, clinical profile, and desire from patients for an oral on-demand therapy, though KalVista priced the drug higher than current injectables, which range from ~$4K-$11K per dose and ~$11K-$17K per attack, the analyst tells investors in a research note.

BofA

Buy

upgrade

$22 -> $37

2025-07-08

Reason

BofA

Price Target

$22 -> $37

2025-07-08

upgrade

Buy

Reason

BofA raised the firm's price target on KalVista to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and no restrictions on type of HAE attack or background LTP usage for patients 12 and older. The firm, which says the approval was in-line with its expectations and it is "encouraged by the broad label," remains "bullish" on Ekterly's differentiation as the only oral on-demand treatment on the market, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV.O) is -4.52, compared to its 5-year average forward P/E of -4.05. For a more detailed relative valuation and DCF analysis to assess Kalvista Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.05

Current PE

-4.52

Overvalued PE

-1.92

Undervalued PE

-6.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.50

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.55

Undervalued EV/EBITDA

-1.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

165.50

Current PS

0.00

Overvalued PS

693.73

Undervalued PS

-362.73

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 7382.63% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KALV News & Events

Events Timeline

No data

News

9.5

12-03Benzinga

Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday

9.0

12-03Benzinga

Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data

8.0

11-26NASDAQ.COM

Significant Options Trading on Wednesday: WMT, KALV, MTDR

People Also Watch

Frequently Asked Questions

What is Kalvista Pharmaceuticals Inc (KALV) stock price today?

The current price of KALV is 16.9 USD — it has decreased -0.06 % in the last trading day.

What is Kalvista Pharmaceuticals Inc (KALV)'s business?

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

What is the price predicton of KALV Stock?

What is Kalvista Pharmaceuticals Inc (KALV)'s revenue for the last quarter?

Kalvista Pharmaceuticals Inc revenue for the last quarter amounts to 13.69M USD, decreased % YoY.

What is Kalvista Pharmaceuticals Inc (KALV)'s earnings per share (EPS) for the last quarter?

Kalvista Pharmaceuticals Inc. EPS for the last quarter amounts to -0.92 USD, increased 9.52 % YoY.

What changes have occurred in the market's expectations for Kalvista Pharmaceuticals Inc (KALV)'s fundamentals?

The market is revising Upward the revenue expectations for KalVista Pharmaceuticals, Inc. (KALV) for FY2025, with the revenue forecasts being adjusted by 111.82% over the past three months. During the same period, the stock price has changed by 25.19%.

How many employees does Kalvista Pharmaceuticals Inc (KALV). have?

Kalvista Pharmaceuticals Inc (KALV) has 270 emplpoyees as of December 16 2025.

What is Kalvista Pharmaceuticals Inc (KALV) market cap?

Today KALV has the market capitalization of 854.74M USD.